BiotechTube

AZD1222

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

COVID-19, Vaccine Adverse Events of Special Interest

Conditions

COVID-19, Vaccine Adverse Events of Special Interest

Trial Timeline

Feb 18, 2022 → Jan 24, 2024

NCT ID
NCT05126992

About AZD1222

AZD1222 is a pre-clinical stage product being developed by AstraZeneca for COVID-19, Vaccine Adverse Events of Special Interest. The current trial status is completed. This product is registered under clinical trial identifier NCT05126992. Target conditions include COVID-19, Vaccine Adverse Events of Special Interest.

What happened to similar drugs?

7 of 20 similar drugs in COVID-19, Vaccine Adverse Events of Special Interest were approved

Approved (7) Terminated (4) Active (11)
✅mRNA-1283.251 Variant-containing FormulationModernaApproved
✅AZD1222AstraZenecaApproved
✅AZD1222AstraZenecaApproved
✅Rivaroxaban 10 mgBayerApproved
✅Novavax COVID-19 vaccine (2023-2024 formula XBB containing) + Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)NovavaxApproved
✅protein subunit: Novavax COVID-19 vaccine + Pfizer mRNA COVID-19 vaccineNovavaxApproved
✅NVX-CoV2705 + PlaceboNovavaxApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT05126992Pre-clinicalCompleted
NCT05057897ApprovedTerminated
NCT04914832ApprovedCompleted
NCT04540393Phase 3Withdrawn

Competing Products

20 competing products in COVID-19, Vaccine Adverse Events of Special Interest

See all competitors
ProductCompanyStageHype Score
mRNA-1283.251 Variant-containing FormulationModernaApproved
0
mRNA-1283.222ModernaPhase 3
0
COVID-19 VaccineModernaPreclinical
0
mRNA-1083ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0
Moderna COVID-19 VaccineModernaPreclinical
0
Gam-COVID-VacDr. Reddy's LaboratoriesPhase 2/3
31
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboSinopharmPhase 2
31
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
29
Gimsilumab + PlaceboRoivant SciencesPhase 2
32
Icosapent ethylAmarin CorporationPhase 2
25
Bamlanivimab + Placebo + EtesevimabEli LillyPhase 3
40
InfliximabCelltrionPhase 2
35
CT-P63 and CT-P66 / PlaceboCelltrionPhase 3
32
Enzalutamide PillAstellas PharmaPhase 2
27
S-892216 + PlaceboShionogiPhase 2
35
S-892216 + CarbamazepineShionogiPhase 1
29
FOY-305 + PlaceboOno PharmaceuticalPhase 3
40
DesidustatZydus LifesciencesPhase 2
35
LY3819253 + PlaceboEli LillyPhase 1
29